Adama Ltd. Class A SZSE:000553

ADAMA : Third Quarter 2025 Q&A Filings

Published

Source: MarketScreener

Stock Code: 000553(200553) Stock Abbreviation: ADAMA A(B) Announcement No.2025-33

The Company and all members of its board of directors hereby confirm that all information disclosed herein is true, accurate and complete with no false or misleading statement or material omission.



ADAMA LTD. THIRD QUARTER REPORT 2025

ADAMA Ltd. (hereinafter referred to as "the Company") is a global leader in crop protection, providing solutions to farmers across the world to combat weeds, insects and disease. ADAMA has one of the widest and most diverse portfolios of active ingredients in the world, state-of-the art R&D, manufacturing and formulation facilities, together with a culture that empowers our people in markets around the world to listen to farmers and ideate from the field. This uniquely positions ADAMA to offer a vast array of distinctive mixtures, formulations and high-quality differentiated products, delivering solutions that meet local farmer and customer needs in dozens of countries globally, with direct presence in all top 20 markets.

Please see important additional information and further details included in the Annex. October 2025 Important Notice The Company's Board of Directors, Board of Supervisors, directors, supervisors and senior managers confirm that the content of the Report is true, accurate and complete and contains no false statements, misleading presentations or material omissions, and assume joint and several legal liability arising therefrom. Gaël Hili, the person leading the Company (Pres ident and Chief Executive Officer) as well as its legal representative, and Efrat Nagar, the person leading the accounting function (Chief Financial Officer), hereby assert and confirm the truthfulness, accuracy and completeness of the Financial Report. The Third Quarter Report has not been audited. This Report has been prepared in both Chinese and English. Should there be any discrepancy between the two versions, the Chinese version shall prevail.
  1. Main accounting and financial results

    1. Whether the Company performs any retroactive adjustments to, or restatements of, its accounting data of last year due to change in accounting policies or correction of accounting errors

      • Yes √ No

        July - September 2025

        +/- (%)

        January -September 2025

        +/- (%)

        Operating revenues (RMB'000)

        6,654,225

        0.62%

        21,678,425

        0.72%

        Net loss attributable to shareholders of the Company (RMB'000)

        (342,454)

        63.69%

        (422,806)

        77.00%

        Net loss attributable to shareholders of the Company excluding non-recurring profit and loss (RMB'000)

        (372,499)

        61.92%

        (522,256)

        72.87%

        Net cash flow from operating activities (RMB'000)

        635,282

        -43.84%

        2,373,860

        -17.06%

        Basic EPS (RMB/share)

        (0.1470)

        63.69%

        (0.1815)

        77.00%

        Diluted EPS (RMB/share)

        N/A

        N/A

        N/A

        N/A

        Weighted average return on net assets

        (1.82%)

        2.71 pp

        (2.26%)

        6.46 pp

        End of Reporting Period

        End of last year

        +/- (%)

        Total assets (RMB'000)

        49,930,633

        50,059,777

        -0.26%

        Net assets attributable to shareholders (RMB'000)

        18,453,345

        18,991,094

        -2.83%

    2. Non-Recurring profit/loss

      √ Applicable □ Not applicable

      Unit: RMB'000

      Item

      July -September

      2025

      January -September

      2025

      Note

      Gains/losses on the disposal of non-current assets (including the offset part of asset impairment provisions)

      9,545

      14,599

      -

      Government grants recognized through profit or loss (excluding government grants closely related to business of the Company and given at a fixed quota or amount in accordance with government's uniform

      standards)

      7,827

      12,938

      -

      Custodian fees earned from entrusted operation

      2,574

      2,574

      -

      Recovery or reversal of provision for bad debts which is assessed individually during the years

      8,298

      46,445

      -

      Post vesting fair value revaluation of cash-settled share based payment

      4,414

      11,992

      -

      Gains or losses arising from the holding or disposal of financial assets or financial liabilities by non-financial corporations, except for effective hedging related to the

      normal operating of the Company

      -

      30,714

      -

      Other non-operating income and expenses other than the above

      2,160

      3,980

      -

      Less: Income tax effects

      4,773

      23,792

      -

      Total

      30,045

      99,450

      -

      Explanation of other profit or loss that meets the definition of non-recurring profit or loss

      • Applicable √ Not applicable

        No such cases in the Reporting Period.

        Explanation of why the Company classified an item as non-recurring profit/loss according to the definition in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering their Securities to the Public. Non-recurring Profit and Loss, and reclassified any non-recurring profit/loss items are given as examples in the said explanatory announcement to recurrent profit/loss

      • Applicable √ Not applicable

        No such cases in the Reporting Period.

    3. Changes in main accounting statement items and financial indicators in the Reporting Period, as well as reasons for the changes

      √ Applicable □ Not applicable

      General Crop Protection (CP) Market Environment1

      Through the first nine months of 2025, channel inventory returned to pre-pandemic levels in most countries, allowing crop protection demand recovery. Pricing pressure remains high, driven by production over-capacity of active ingredients. Crop commodity prices remain stably low and coupled with the high-interest rate environment, farmer profitability remains tight leading to just-in-time purchasing patterns.

      Geopolitical Situation

      ADAMA is headquartered and has three manufacturing sites in Israel. The regional tensions which escalated on October 7, 2023, continued to have no material impact to-date on the Company's ability to support its markets or its consolidated financial results.

      ADAMA is a global company with manufacturing and formulation facilities in several locations around the world, principally in Israel, China and Brazil. The Company's management appointed a dedicated task force to analyze implications of US tariff policies and to closely monitor and manage the situation and its potential impact on its global network. Despite the uncertainty regarding the US tariff policies, the Company currently expects that the impact on its operations and business results will be immaterial.

      January -September 2025 (000'RMB)

      Same period last year (000'RMB)

      +/-%

      January -September 2025 (000'USD)

      Same period last year (000'USD)

      +/-%

      Operating income (Revenues)

      21,678,425

      21,523,293

      0.72%

      3,024,742

      3,027,945

      -0.11%

      Cost of goods sold

      16,004,956

      16,748,146

      -4.44%

      2,233,171

      2,356,131

      -5.22%

      Sales & Marketing expenses

      2,950,375

      3,408,333

      -13.44%

      411,737

      479,481

      -14.13%

      General & Administrative expenses

      1,089,510

      817,172

      33.33%

      152,041

      114,955

      32.26%

      R&D expenses

      307,417

      319,977

      -3.93%

      42,890

      45,014

      -4.72%

      Financial Expenses

      1,544,466

      1,220,073

      26.59%

      215,373

      171,629

      25.49%

      ‌1Sources: AgbioInvestor Quarterly report (September 2025), peer quarterly financial results, internal sources.

      January -September 2025

      (000'RMB)

      Same period last year (000'RMB)

      +/-%

      January -September 2025

      (000'USD)

      Same period last year (000'USD)

      +/-%

      Gain (Loss) from Changes in Fair Value

      4,781

      (235,775)

      102.03%

      574

      (33,184)

      101.73%

      Total Net Financial Expenses

      1,539,685

      1,455,848

      5.76%

      214,799

      204,813

      4.88%

      Total loss

      (417,446)

      (1,442,604)

      71.06%

      (58,307)

      (202,873)

      71.26%

      Income tax expenses

      5,360

      395,508

      -98.64%

      801

      55,643

      -98.56%

      Net loss attributable to shareholders of the Company

      (422,806)

      (1,838,112)

      77.00%

      (59,108)

      (258,516)

      77.14%

      EBITDA

      2,706,104

      1,790,580

      51.13%

      377,526

      251,953

      49.84%

      Q3 2025 (000'RMB)

      Q3 2024 (000'RMB)

      +/-%

      Q3 2025 (000'USD)

      Q3 2024 (000'USD)

      +/-%

      Operating income (Revenues)

      6,654,225

      6,613,004

      0.62%

      933,411

      929,451

      0.43%

      Cost of goods sold

      4,974,783

      5,274,072

      -5.67%

      697,816

      741,264

      -5.86%

      Sales & Marketing expenses

      974,707

      1,044,957

      -6.72%

      136,724

      146,867

      -6.91%

      General & Administrative expenses

      354,643

      280,906

      26.25%

      49,739

      39,480

      25.99%

      R&D expenses

      90,624

      101,870

      -11.04%

      12,713

      14,319

      -11.22%

      Financial Expenses

      520,126

      596,427

      -12.79%

      72,943

      83,826

      -12.98%

      Gain (Loss) from Changes in Fair Value

      11,274

      (39,283)

      128.70%

      1,581

      (5,525)

      128.62%

      Total Net Financial Expenses

      508,852

      635,710

      -19.96%

      71,362

      89,351

      -20.13%

      Total loss

      (291,867)

      (871,175)

      66.50%

      (40,903)

      (122,441)

      66.59%

      Income tax expenses

      50,587

      72,072

      -29.81%

      7,096

      10,129

      -29.94%

      Net loss attributable to shareholders of the Company

      (342,454)

      (943,246)

      63.69%

      (47,999)

      (132,570)

      63.79%

      EBITDA

      741,865

      395,826

      87.42%

      104,087

      55,636

      87.09%

      Note: Since the functional currency of main overseas subsidiaries is the USD, and the Company's management review of the Company's performance is based on the USD results, following explanations and analysis are based on USD-denominated numbers as listed above.

      Analysis of Financial Highlights
      1. Revenues

        Revenues in the third quarter were stable (1% in RMB; 0% in CER) reaching $933 million, mainly reflecting the combined results of a 1% increase in volume and a 1% decrease in prices. The higher volumes reflected the gradual recovery of market demands and improvement of channel inventories in most regions. Prices remained weak mainly due to low prices of active ingredients in light of overcapacity, as well as a high-interest rate environment and low commodity prices, which put pressure on distributors and farmers.

        Revenues in the first nine months were also stable (1% in RMB; 1% in CER) reaching $3,025 million. The stabilization of revenues in the first nine months was driven by volume growth of 3% offsetting a decrease in prices of 3%.

        Regional Sales Performance

        Q3 2025

        $m

        Q3 2024

        $m

        Change USD

        9M 2025

        $m

        9M 2024

        $m

        Change USD

        Europe, Africa & Middle East (EAME)2

        233

        216

        8%

        903

        911

        -1%

        North America

        164

        158

        4%

        659

        572

        15%

        Latin America

        312

        287

        9%

        675

        687

        -2%

        Asia Pacific3

        225

        269

        -16%

        789

        859

        -8%

        Of which China

        91

        109

        -17%

        400

        384

        4%

        Total

        933

        929

        0%

        3,025

        3,028

        0%

        Note: the numbers in this table may not sum due to rounding.

        Europe, Africa & Middle East (EAME): Volumes and revenue in EAME increased in the third quarter, though significant declines in Turkey in the first quarter impacted the year-to-date results. Pricing continued to decline in light of intense competition. Foreign exchange rates had positive impact in the third quarter.

        North America: In the US Ag market, though slightly down in the third quarter, was significantly up in the first nine months following improvements in volumes and prices. Similarly in Canada, while the third quarter was flat with an increase in volume offset by a decrease by prices, for the nine months volumes are significantly up. Consumer & Professional Solutions experienced increased volumes and flat prices for both the third quarter and year-to-date.

        Latin America: In Brazil, revenues were significantly up in the third quarter, resulting in higher revenues also for the first nine months compared to the previous year. Growth was driven by increased volumes, while the third quarter also experienced modest pricing increases. In the rest of LATAM lower volumes, prices, and revenues were reported in the third quarter and the first nine months, primarily in Paraguay and Argentina, due to channel destocking and just-in-time purchasing behavior.

        Asia-Pacific: India experienced significant declines in the third quarter revenues, primarily due to lower volumes driven by extreme weather conditions and lower prices. In the rest of APAC (excluding India and China), sales and volumes were

        ‌2As part of ADAMA's business optimization program, on January 1, 2025, South Africa was reclassified from the APAC region to EAME. To enable meaningful comparisons, the 2024 data presented here includes South Africa under EAME.

        slightly up for the quarter, despite ongoing pricing pressures.

        In China, sales in the third quarter mainly reflected the impacts of lower non-ag sales, partially compensated by the increase of AI sales. Non-ag sales declined following implementation of the Company's strategic decision to pivot away from manufacturing some basic chemical products, and weaker market demands. Higher AI sales were driven by volume growth due to the expansion of new distribution channels and supported by the recovery of global demand. Sales of the formulations business stabilized, still reflecting relatively high channel inventories and severe market competition. Supported by the growth in the first half, sales in China in the first nine months increased compared to last year.

      2. Cost of Goods and Gross Profit

        The higher gross profit and margin in the third quarter and first nine months mainly reflected the positive impacts of lower costs due to improved operational efficiency and lower costs of inventory sold as well as higher volume, more than compensating for lower prices.

      3. Operating Expenses:

        Operating expenses include Sales and Marketing, General and Administration and R&D.

        The operating expenses in both the third quarter and first nine months were lower mainly because last year there were one-off expenses related to a legal claim of product liabilities which offset the higher restructuring and advisory costs in 2025. In the third quarter, the benefits were offset by the increase in expenses attributed to company success-based employee compensation due to improved 2025 results to-date. In the first nine months, the positive impacts following implementation of the Fight Forward plan in 2025 and that in H1 last year an update of registration amortization was recorded contributed to the decrease in operating expenses.

        In addition to that, for Q3 and 9M of both 2024 and 2025, the Company continued recording following charges in its sales and marketing expenses at a similar amount, which incurred due to mergers and acquisitions in recent years, mainly: (i) non-cash amortization charges in respect of transfer assets received from Syngenta related to the 2017 ChemChina-Syngenta acquisition; and (ii) non-cash amortization net charges related to intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions, with no impact on the ongoing performance of the companies acquired.

        Non-operational charges affected the Company's reported operating expenses amounting to RMB 176 million ($25 million) in Q3 2025 in comparison to RMB 167 million ($23 million) in Q3 2024, and RMB 519 million ($73 million) in 9M 2025 in comparison to RMB 639 million ($90 million) in 9M 2024. For details of the non-operational charges, please refer to the Annex to the Report.

      4. Financial Expenses

        "Financial Expenses" alone mainly reflect interest payments on corporate bonds and bank loans as well as foreign exchange gains/losses on the bonds and other monetary assets and liabilities before the Company carries out any hedging. The impact of Financial Expenses (before hedging) is an expense of RMB 1,544 million ($215 million) for the nine months of 2025 compared with an expense of RMB 1,220 million ($172 million) for the corresponding period in 2024.

        Given the global nature of its operational activities and the composition of its assets and liabilities, the Company, in the ordinary course of its business, uses foreign currency derivatives (forwards and options) to hedge the cash flow risks associated with existing monetary assets and liabilities that may be affected by exchange rate fluctuations. "Gains/Losses from Changes in Fair Value" which recorded the hedging costs and impacts among others amounted to a net gain of RMB 5 million ($0.6 million) in the first nine months of 2025, compared with a net loss of RMB 236 million ($33 million) in the corresponding period in 2024.

        The aggregate of Financial Expenses and Gains/Losses from Changes in Fair Value (hereinafter as "Total Net Financial Expenses"), which more comprehensively reflects the financial expenses of the Company in supporting its main business and protecting its monetary assets/liabilities, amounts to RMB 1,540 million ($215 million) in the nine months of 2025 compared with RMB 1,456 million ($205 million) in the corresponding period in 2024.

        In the first nine months, Total Net Financial Expenses increased mainly because in 2024 there was a RMB 239 million ($34 million) income from revaluation of the put options attributed to minority stakes in controlled subsidiaries. Excluding this one-time gain last year, Total Net Financial Expenses were lower in the first nine months primarily positively impacted by a bond buyback that was executed in late Q2 by a fully-controlled subsidiary of the Company, as well as the lower hedging costs related to the Israeli Shekel.

      5. Income Tax Expenses

      The Company recorded tax expenses mainly because losses that were primarily incurred by subsidiaries with relatively lower tax rates, while some of them did not create deferred tax assets on the losses. On the other hand, the subsidiaries that generated profit have a higher tax rate.

      The tax expenses in first nine months of 2025 are lower compared to the first nine months of 2024 due to (1) lower losses in subsidiaries that did not create deferred tax assets; (2) tax income raised by the accounting method of calculation of tax assets related to unrealized profits; and (3) foreign exchange impact of the stronger BRL in 2025 compared with tax expenses due to the weakness of the BRL in the first nine month of 2024.

      Changes in main assets and liabilities

      Unit: RMB'000

      Assets and liabilities

      End of Reporting

      Period

      End of last year

      +/- (%)

      Explanation

      Derivative financial assets

      334,747

      483,822

      -30.81%

      Change due to realization and revaluation of derivatives

      Other receivables

      640,870

      1,147,469

      -44.15%

      Mainly decrease in receivables in respect of securitization transaction

      Bills payable

      647,860

      439,495

      47.41%

      Increase in the procurement of goods

      Other payables

      1,872,012

      1,417,319

      32.08%

      Mainly increase in liabilities in respect of securitization transaction and accrued expenses

      Short-term loans

      6,394,069

      4,748,720

      34.65%

      Debt replacement

      Long-term loans

      1,442,948

      2,166,625

      -33.40%

      Repaid loans

  2. Use of Raised Funds

    • Applicable √ Not applicable

    No such cases in the Reporting Period.

  3. Information regarding the Shareholders

    1. Total number of ordinary shareholders and preference shareholders who had resumed their voting rights, and shareholdings of top 10 shareholders at the period-end

      Unit: share

      Total Number of Common Shareholders as of the End of the

      36,215 (the number of ordinary A share shareholders is 24,837; the

      Total Number of Preference Shareholders with Vote Right

      0

      Reporting Period

      number of B share shareholders is 11,378)

      Restored (if any) as of the End of the Reporting Period

      Shareholding of Top 10 Shareholders (Excluding the Shares Lent through Refinancing)

      Name of

      Shareholder

      Nature of Shareholder

      Holding Percentage (%)

      Number of Shareholding at the End of the Reporting Period

      Number of Common Shares Held Subject to Trading Moratorium

      Pledged, Marked or Frozen Shares

      Status of Shares

      Status of Shares

      Syngenta Group Co., Ltd.

      State-owned Legal Person

      78.47%

      1,828,137,961

      --

      --

      --

      China Structural Reform Fund

      State-owned Legal Person

      1.44%

      33,557,046

      --

      --

      --

      China Cinda Asset Management Co.,

      Ltd.

      State-owned Legal Person

      1.34%

      31,115,916

      --

      --

      --

      Hong Kong Securities Clearing

      Company Ltd. (HKSCC)

      Overseas

      Legal Person

      0.62%

      14,414,719

      --

      --

      --

      Wu Feng

      Domestic Natural Person

      0.34%

      7,863,412

      --

      --

      --

      Zhu Shenglan

      Domestic Natural

      Person

      0.32%

      7,350,000

      --

      --

      --

      Qichun County

      State-owned Assets Center

      State-owned Legal Person

      0.18%

      4,169,266

      Liu Minqin

      Domestic Natural Person

      0.16%

      3,832,446

      --

      --

      --

      Zhang Jianwei

      Domestic Natural Person

      0.13%

      3,109,701

      --

      --

      --

      GUOTAI JUNAN SECURITIES

      (HONG KONG) LIMITED

      Overseas

      Legal Person

      0.13%

      3,006,597

      --

      --

      --

      Shares Held by Top 10 Shareholders Not Subject to Trading Moratorium (Excluding the Shares Lent through Refinancing and Restricted Shares of Executives)

      Name of Shareholders

      Number of Shares Held Not Subject

      to Trading Moratorium at the End of the Period

      Type of Shares

      Type of Shares

      Amount

      Syngenta Group Co., Ltd.

      1,828,137,961

      RMB Ordinary Share

      1,828,137,961

      China Structural Reform Fund

      33,557,046

      RMB Ordinary Share

      33,557,046

      China Cinda Asset

      Management Co., Ltd.

      31,115,916

      RMB Ordinary Share

      31,115,916

      Hong Kong Securities

      Clearing Company Ltd. (HKSCC)

      14,414,719

      RMB Ordinary Share

      14,414,719

      Wu Feng

      7,863,412

      RMB Ordinary Share

      7,863,412

      Zhu Shenglan

      7,350,000

      RMB Ordinary Share

      7,350,000

      Qichun County State-owned Assets Center

      4,169,266

      RMB Ordinary Share

      4,169,266

      Liu Minqin

      3,832,446

      RMB Ordinary Share

      3,832,446

      Zhang Jianwei

      3,109,701

      RMB Ordinary Share

      3,109,701

      GUOTAI JUNAN SECURTIES (HONG KONG) LIMITED

      3,006,597

      Domestically Listed Shares in Foreign Currencies

      3,006,597

      Explanation on associated relationship among the above-mentioned

      shareholders, or

      Syngenta Group Co., Ltd. is neither a related party to any other shareholders listed above, nor any acting-in-concert party as prescribed in the Administrative Methods for Acquisition of Listed Companies. It is unknown whether the other shareholders are related parties or

      acting-in-concert parties as prescribed in the Administrative Methods for Acquisition of Listed

      explanation on acting-in-concert

      Companies.

      Particular about the top ten shareholder participating in the securities financing business (if any)

      Shareholder Wu Feng held 4,882,586 shares of the Company through a common securities account and 2,980,826 shares of the Company through a credit collateral securities trading account, altogether 7,863,412 shares. Shareholder Liu Minqin held 403,746 shares of the Company through a common securities account of the Company and 3,428,700 shares of the Company through a credit collateral securities trading account, altogether 3,832,446

      shares.

      Shareholders holding more than 5% of shares, top ten shareholders and top ten shareholders with unlimited shares in circulation participating in the shares lending through refinancing arrangement

      □Applicable √ Not applicable

      Change of top ten shareholders and top ten shareholders with unlimited shares in circulation from the previous period due to the shares lending/returning through refinancing arrangement

      • Applicable √ Not applicable

    2. Total number of preference shareholders and shareholdings of the top 10 of such at the period-end

      • Applicable √ Not applicable

  4. Other Significant Events

    • Applicable √ Not applicable

  5. Financial Statements

  1. Financial Statements

    1. Consolidated balance sheet

      Prepared by ADAMA Ltd.

      30 September 2025

      Unit: RMB'000

      Item

      September 30,

      2025

      December 31,

      2024

      Item

      September 30,

      2025

      December 31,

      2024

      Current assets:

      Current liabilities:

      Cash at bank and on hand

      3,734,324

      3,630,608

      Short-term loans

      6,394,069

      4,748,720

      Financial assets held for trading

      12,641

      1,035

      Derivative financial liabilities

      291,732

      278,580

      Derivative financial assets

      334,747

      483,822

      Bills payable

      647,860

      439,495

      Bills receivable

      147,568

      65,565

      Accounts payable

      5,309,492

      4,934,865

      Accounts receivable

      7,804,471

      7,977,830

      Contract liabilities

      1,493,561

      1,810,764

      Receivables financing

      96,351

      144,763

      Employee benefits payable

      808,113

      851,784

      Prepayments

      342,295

      313,542

      Taxes payable

      449,404

      516,761

      Other receivables

      640,870

      1,147,469

      Other payables

      1,872,012

      1,417,319

      Inventories

      11,968,957

      11,164,663

      Non-current liabilities due within one year

      1,998,547

      2,230,713

      Other current assets

      1,180,676

      988,093

      Other current liabilities

      1,203,799

      784,456

      Total current assets

      26,262,900

      25,917,390

      Total current liabilities

      20,468,589

      18,013,457

      Non-current assets:

      Non-current liabilities:

      Long-term receivables

      351,126

      159,813

      Long-term loans

      1,442,948

      2,166,625

      Long-term equity investments

      38,839

      30,227

      Debentures payable

      5,281,141

      6,320,157

      Other equity investments

      130,606

      131,473

      Lease liabilities

      628,209

      610,415

      Investment properties

      19,280

      20,509

      Long-term accounts payable

      176,635

      191,103

      Fixed assets

      9,547,158

      9,762,895

      Long-term employee benefits payables

      536,835

      543,855

      Construction in progress

      1,822,558

      1,996,892

      Provisions

      391,690

      316,490

      Right-of-use assets

      547,539

      557,159

      Deferred tax liabilities

      204,862

      283,081

      Intangible assets

      4,389,981

      4,796,655

      Other non-current liabilities

      2,346,379

      2,623,500

      Goodwill

      5,017,236

      5,074,283

      Total non-current liabilities

      11,008,699

      13,055,226

      Deferred tax assets

      1,452,771

      1,291,654

      Total liabilities

      31,477,288

      31,068,683

      Other non-current assets

      350,639

      320,827

      Shareholders' equity:

      Total non-current assets

      23,667,733

      24,142,387

      Share capital

      2,329,812

      2,329,812

      Total assets

      49,930,633

      50,059,777

      Capital reserves

      12,950,464

      12,950,464

      Other comprehensive income

      1,687,420

      1,721,028

      Special reserves

      3,576

      10,798

      Surplus reserves

      298,610

      298,610

      Retained earnings

      1,183,463

      1,680,382

      Total equity attributed to the shareholders of the company

      18,453,345

      18,991,094

      Non-controlling interests

      -

      -

      Total equity

      18,453,345

      18,991,094

      Total liabilities and equity

      49,930,633

      50,059,777

      Gael Hili

      Legal representative

      Efrat Nagar

      Chief of the accounting work

      Efrat Nagar

      Chief of the accounting organ

    2. Consolidated income statement for the period from the year-beginning to the end of the Reporting Period

      Unit: RMB'000

      Item

      January-September, 2025

      January-September, 2024

      1. Total operating Income

      21,678,425

      21,523,293

      Less: Cost of sales

      16,004,956

      16,748,146

      Taxes and surcharges

      72,462

      71,856

      Selling and Distribution expenses

      2,950,375

      3,408,333

      General and Administrative expenses

      1,089,510

      817,172

      Research and Development expenses

      307,417

      319,977

      Financial expenses

      1,544,466

      1,220,073

      Including: Interest expense

      527,096

      792,488

      Interest income

      101,281

      181,974

      Add: Investment income, net

      7,464

      8,386

      Including: Income from investment in associates

      and joint ventures

      7,464

      6,062

      Gain (Loss) from changes in fair value

      4,781

      (235,775)

      Credit impairment losses

      (108,746)

      (85,475)

      Asset Impairment losses

      (63,997)

      (157,247)

      Gain from disposal of assets

      14,599

      39,823

      2. Operating loss

      (436,660)

      (1,492,552)

      Add: Non-operating income

      38,793

      69,143

      Less: Non-operating expense

      19,579

      19,195

      3. Total loss

      (417,446)

      (1,442,604)

      Less: income tax expense (income)

      5,360

      395,508

      4. Net loss

      (422,806)

      (1,838,112)

      4.1 Classified by nature of operations

      4.1.1 Continuing operations

      (422,806)

      (1,838,112)

      4.2 Classified by ownership

      4.2.1 Shareholders of the Company

      (422,806)

      (1,838,112)

      4.2.2 Non-controlling interests

      -

      -

      5. Other comprehensive income (loss) net of tax

      (33,608)

      (229,757)

      Other comprehensive income (loss) net of tax attributable to

      shareholders of the Company

      (33,608)

      (229,757)

      5.1 Items that will not be reclassified into profit/loss

      (2,882)

      4,545

      5.1.1 Re-measurement of defined benefit plan liability

      (2,882)

      4,545

      5.2 Items that were or will be reclassified to profit or loss

      (30,726)

      (234,302)

      5.2.1 Effective portion of gains or loss of cash flow hedge

      (35,542)

      (7,805)

      5.2.2 Translation differences of foreign financial statements

      4,816

      (226,497)

      Other comprehensive income net of tax attributable to Non-controlling

      interests

      -

      -

      6. Total comprehensive loss for the period

      (456,414)

      (2,067,869)

      Total comprehensive loss attributable to shareholders

      of the Company

      (456,414)

      (2,067,869)

      Total comprehensive income attributable to Non-controlling interests

      -

      -

      7. Earnings (loss) per share

      7.1 Basic earnings (loss) per share (RMB/ share)

      (0.1815)

      (0.7890)

      7.2 Diluted earnings per share (RMB/ share)

      N/A

      N/A

      Gael Hili

      Legal representative

      Efrat Nagar

      Chief of the accounting work

      Efrat Nagar

      Chief of the accounting organ

    3. Consolidated cash flow statement for the period from the year-beginning to the end of the Reporting Period

      Unit: RMB'000

      Item

      January-September, 2025

      January-September, 2024

      1. Cash flows from operating activities:

      Cash received from sale of goods and rendering of services

      22,008,090

      20,852,442

      Refund of taxes and surcharges

      167,870

      165,239

      Cash received relating to other operating activities

      105,894

      343,229

      Sub-total of cash inflows from operating activities

      22,281,854

      21,360,910

      Cash paid for goods and services

      14,138,110

      12,964,858

      Cash paid to and on behalf of employees

      2,906,459

      2,997,725

      Payments of taxes and surcharges

      435,698

      428,866

      Cash paid relating to other operating activities

      2,427,727

      2,107,229

      Sub-total of cash outflows from operating activities

      19,907,994

      18,498,678

      Net cash flows from operating activities

      2,373,860

      2,862,232

      2. Cash flows from investing activities :

      Cash receipts from disposal of investments

      55,050

      83,249

      Cash received from investment income

      3,301

      -

      Net cash received from disposal of fixed assets, intangible assets

      and other long-term assets

      46,283

      242,278

      Cash received for other investing activities

      -

      2,325

      Sub-total of cash inflows from investing activities

      104,634

      327,852

      Cash paid to acquire fixed assets, intangible assets and other

      long-term assets

      865,720

      1,074,140

      Net cash paid to acquire subsidiaries or other business units

      56,272

      -

      Cash paid for other investing activities

      124,725

      120,132

      Sub-total of cash outflows from investing activities

      1,046,717

      1,194,272

      Net cash flows from investing activities

      (942,083)

      (866,420)

      3. Cash flows from financing activities:

      Cash received from borrowings

      1,835,663

      1,311,257

      Cash received relating to other financing activities

      1,652,577

      805,600

      Sub-total of cash inflows from financing activities

      3,488,240

      2,116,857

      Cash repayment of borrowings

      3,664,529

      3,588,782

      Cash payment for dividends, profit distributions or interest

      698,885

      788,921

      Including: dividends paid to non-controlling interest

      74,113

      69,512

      Cash paid relating to other financing activities

      533,136

      442,213

      Sub-total of cash outflows from financing activities

      4,896,550

      4,819,916

      Net cash flows from financing activities

      (1,408,310)

      (2,703,059)

      4. Effect of foreign exchange rate changes on cash and cash

      equivalents

      (27,731)

      (21,111)

      5. Net increase (decrease) in cash and cash equivalents

      (4,264)

      (728,358)

      Add: Cash and cash equivalents at the beginning of the period

      3,583,963

      4,857,358

      6. Cash and cash equivalents at the end of the period

      3,579,699

      4,129,000

  2. Impact of initial application of new accounting standards on the opening balances of current year

    • Applicable √ Not applicable

  3. Auditor's report

Is this Report audited?

  • Yes √ No

This Report is unaudited.

Board of Directors ADAMA Ltd.

October 30, 2025